Specifically, PPARα activation may contribute to the prevention of NAFLD and NASH aggravation because the PPARα-activated target genes have roles in anti-inflammation and reduction of lipid accumulation in the liver. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.